Wondering if Jardiance is a GLP-1 medication? Learn the difference and how licensed providers may help guide your treatment plan.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Eden connects individuals with licensed healthcare providers who independently evaluate and determine personalized treatment plans.
If you’ve been hearing about medications like Ozempic or Mounjaro and are wondering how Jardiance fits into the picture, you're not alone. While they may all seem part of the same conversation around weight and metabolic health, they actually work in different ways.
In this article, we’ll clarify what type of medication Jardiance is, how it works, and how it compares to GLP-1 medications. Whether you're just beginning to explore your options or considering speaking to a licensed provider, understanding the differences can help you ask the right questions.
Jardiance (empagliflozin) is a prescription medication that belongs to a class called SGLT2 inhibitors. These medications work differently from GLP-1 receptor agonists. Rather than influencing appetite or insulin secretion, Jardiance helps the kidneys remove glucose from the body through the urine.
Jardiance is FDA-approved to treat adults with type 2 diabetes and is also approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and heart disease. However, it is not approved for weight loss or weight management.
No, Jardiance is not a GLP-1 medication.
GLP-1 (glucagon-like peptide-1) receptor agonists mimic a natural hormone that may help regulate blood sugar and appetite. These medications may slow digestion, increase feelings of fullness, and reduce food intake. Medications in this category include semaglutide and tirzepatide.
Jardiance, by contrast, does not impact appetite or digestion. Instead, it supports blood sugar control by acting directly on the kidneys.
{{primary-cta}}
Jardiance blocks a protein in the kidneys called SGLT2. This helps prevent glucose from being reabsorbed into the blood and instead causes it to be eliminated in urine. This action may help lower blood sugar in adults with type 2 diabetes and has been associated with benefits for heart and kidney health in specific populations.
This is fundamentally different from GLP-1 medications, which act on the gut and brain to regulate hunger and insulin release.
Because both Jardiance and GLP-1 medications are used to manage blood sugar in type 2 diabetes, they are commonly discussed together in conversations about type 2 diabetes treatment. Some providers may even prescribe them together in specific cases, depending on an individual’s medical history and health goals.
However, only certain GLP-1 medications are FDA-approved for weight management. Jardiance is not one of them.
While some people taking Jardiance may experience modest weight loss, this is not its primary function or an FDA-approved use. Any weight changes are typically the result of fluid loss or changes in blood sugar, not appetite suppression.
If weight management is a priority for you, a licensed provider may consider FDA-approved GLP-1 medications as part of your treatment plan. These decisions depend on a range of personal health factors and should be reviewed by a licensed healthcare provider during an evaluation.
{{primary-cta}}
Eden is a digital health platform that connects individuals with licensed healthcare providers. These providers may prescribe FDA-approved GLP-1 treatments when appropriate. Eden does not make medications or practice medicine. We empower you to have direct access to trusted clinical care.
If you’re curious whether GLP-1 treatment is right for you, Eden can help you take the first step toward a personalized, evidence-based approach.
Jardiance is not a GLP-1 medication. It works differently and is used for different health goals. If you're navigating your options for weight or metabolic health, understanding these differences may help you make more informed decisions.
Eden connects individuals with licensed healthcare providers who evaluate whether GLP-1 medications may be appropriate. Your provider will guide your treatment, monitor for side effects, and adjust your care plan as needed.
Disclaimer: Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Independent, state-licensed pharmacies fill medications. Eden does not manufacture, own, or dispense any medications. No health claims are made unless supported by multiple peer-reviewed studies. Please consult a licensed healthcare provider before making any medical decisions.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Padda, I. S., Mahtani, A. U., & Parmar, M. (2023, June 3). Sodium-Glucose transport protein 2 (SGLT2) inhibitors. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK576405/
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128. https://doi.org/10.1056/nejmoa1504720
